Search bioRxiv⌕ Search

Biology subjects

Chandra, R. V.

Publications and source records attributed to Chandra, R. V..

3 recordsLinked to original sources

HISTOLOGICAL EVALUATION OF THE EFFICACY OF COLLAGEN MEMBRANE IMPREGNATED WITH RECOMBINANT HUMAN FIBROBLAST GROWTH FACTOR 2 (rhFGF 2) FOR GINGIVAL RECESSION DEFECTS IN BEAGLE DOGS

BACKGROUNDOne of the most common esthetic concerns associated with the periodontal tissues is gingival recession. Many techniques have been introduced to treat gingival recession, including connective tissue grafting, or CTG; various flap designs; GTR membranes. However, their combination with biologic modifiers has not been explored. So, The present animal study aims to histologically compare collagen membrane impregnated with recombinant human fibroblast growth factor-2 (rhFGF-2) with that of plain collagen membrane in the treatment of Millers Class I and II gingival recessions for root coverage and healing process in beagle dogs. MATERIALS AND METHODS18 beagle dogs of ages between 4-6 years were included in the study. The study was conducted as split mouth study on test site collagen membrane impregnated with recombinant human fibroblast growth factor-2 (rhFGF-2) was placed, on control site plain collagen membrane was placed. Histologically bone regeneration, mineralized tissue volume, membrane remnants and clinically recession depth were analysed at baseline, 3 months and 6 months. RESULTSNo significant difference was observed between the test and the control groups from baseline to 3 months (p=0.331 NS) bone regeneration, whereas, significant difference was observed from baseline to 6 months (p=0.008*). The three months histological specimen of the test and control sites showed woven bone (NB) with rich vasculature along with abundant collagen bundles. Remnants of the membrane can also be observed at the periphery with no signs of multinucleated giant cells. The six months histological report of the test site shows matured bone formation, with rich vasculature, but new bone formation was less in control group. Significant difference was seen between test and control groups for mineralized tissue formation at 6-months. (p=0.003). Highly significant difference was seen for membrane degradation in test group (p[≤]0.001**) compared to control group. Significant differences were observed between the test and the control groups for the root coverage from baseline to 3 months. (p=0.008*) and from baseline to 6-months highly significant was observed(p=0.001**). CONCLUSIONThe three months and six months specimens of the test (rhFGF2 membrane) group has shown good amount of bone regeneration and soft tissue healing with limited membrane remnants and reduced recession depth at the test site, when compared to the control group. These results prove that the rhFGF2 growth factor impregnated collagen membrane is highly efficient in treating gingival recession, thus improving the periodontal health.

bioengineering↗

Solving the Variable-Particle Size Quandary of Bone Mills. Development of an Automated Milling System to Generate Graft Particles of Definite Sizes.

There are situations where block grafts have to be milled to convert them into particulate grafts of definite sizes. The objectives of this study were to evaluate the quality of graft particles generated in two sizes from a custom-built automated milling system (AMS) and their biocompatibility in an animal model. A Monetite block was milled in an AMS to generate small (SS group; 0.5-0.8 mm) and medium size (MS group; 1.0-1.2 mm) particles. Measures of particle count, Ferets diameter (dF), particle distribution and size were recorded. Biocompatibility of particles was tested in a rabbit tibial defect model. The average particle size was significantly smaller in the SS group than the MS group (0.68{+/-}0.39 vs 1.10{+/-}0. 79 mm; p[≤]0.001). There were significant to highly significant differences between SS and MS groups in measures of particle count (p[≤]0.001), dF (p=0.02) and size (p[≤]0.001). SS and MS groups had maximum percentage of particles in the 0.6-1mm (71%) and >1mm (70%) ranges respectively. The mineralized tissue volumes across SS, MS when compared to an autogenous block were 68.92{+/-}35.66%, 66.29{+/-}29.21% and 89.83{+/-}19.91% (p=0.003) respectively. The device was able to generate small and medium-size graft particles which were distinct from each other.

scientific communication and education↗

Analysis of Costs and Strategies for Using Academic Research in a Private Dental College to Develop Commercially Viable Products

ABSTRACTBackground & objectives The study had two aims. 1) Analysis of research projects done in our institution from 2014-2019 to identify products with a potential for commercialization and 2) To understand the effect of product-development variables on research projects to improve the quality of future commercialization-oriented trials.Methods 338 clinical trials were grouped into 188 projects under the headings irrigants, diagnostic devices, surgical devices, biomaterials and gels. Trials per project, capital, material costs, labour and the cycle times per trial were calculated. To understand the effect these variables, five hypotheses were generated to test whether greater number of trials, successes, higher capital, more investigators per trial and a longer trial duration will result in a product worthy of commercialization.Results 22 projects had products with a potential for commercialization. Except labour and cycle time (p>0.05), all variables showed significant differences across all projects. Three products were identified as having potential for actual commercialization. It was observed that greater number of trials (χ2=4.6793; p=0.030528) and successes (χ2=20.8134; p<0.00001) in a project along with a higher capital (χ2=12.2662; p=0.000461) will generate a product worthy of commercialization.Interpretation & conclusions The results seem to suggest that in trials for commercialization, emphasis must be placed on implementing multiple, well-designed clinical trials on a device or product to successfully identify whether it is commercialization-worthy or not. Due attention must be given to the financial aspects of the projects as deficiencies may result in negative impact on the flow and outcomes of a clinical trial.Competing Interest StatementThis study is supported by a grant (DST/NSTMIS/05/222/2017-18) under the National Science & Technology Management Information System (NSTMIS), Department of Science and Technology, Government of India. Dr Rama Raju holds a patent on a low-cost oral cancer detection device. Dr R Viswa Chandra has patents pending on a butyrate inactivated recombinant human bone morphogenetic protein-2 (rhBMP-2) gel and basic fibroblast growth factor (bFGF) impregnated collagen membranes. View Full Text

scientific communication and education↗